Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Oryzon Genomics (ORY SM)
Watchlist
54
Analysis
Health Care
•
Spain
Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Oryzon Genomics
•
22 May 2017 17:52
•
Issuer-paid
ORY-2001 and ORY-3001 next in focus
Oryzon’s Q117 financial results were broadly in line with our expectations. The company’s partner, Roche is now solely responsible for ORY-1001’s...
Edison Investment Research
Follow
115 Views
Share
bullish
•
Oryzon Genomics
•
02 May 2017 16:39
•
Issuer-paid
Maturing epigenetics portfolio
Oryzon has been making steady progress with its epigenetics R&D pipeline. Following positive Phase I/IIa trial results in December 2016,...
Edison Investment Research
Follow
19 Views
Share
bullish
•
Oryzon Genomics
•
13 Mar 2017 16:31
•
Issuer-paid
New data further back MS indication
Oryzon has two assets, ORY-1001 and ORY-2001, in the clinical stage of development, with ORY-3001 being investigated for oncology indications in...
Edison Investment Research
Follow
42 Views
Share
bullish
•
Oryzon Genomics
•
09 Dec 2016 16:21
•
Issuer-paid
Expanding clinical R&D pipeline
Oryzon presented more granular data from Phase I/IIa in acute leukaemia at the American Society of Hematology (ASH) meeting after the positive...
Edison Investment Research
Follow
41 Views
Share
First
Previous
8
9
10
11
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x